Anavex reports significant cognitive improvement with blarcamesine in early Alzheimer's patients

From Nasdaq: 2025-04-05 12:12:00

Anavex Life Sciences Corp. announced that continuous treatment with blarcamesine significantly improved clinical decline in early Alzheimer’s disease patients, with no associated neuroimaging adverse events or deaths related to the study drug. The ATTENTION-AD trial followed participants for up to 192 weeks, showing a significant difference in cognitive function between early and late start treatment groups. Results suggest that starting blarcamesine earlier in disease progression leads to greater cognitive stability. An ADAS-Cog13 score difference larger than 2 points is considered clinically meaningful improvement. Similar results were seen in the ADCS-ADL analysis, confirming the beneficial treatment effect of blarcamesine.



Read more at Nasdaq: Anavex Life Sciences Reports Long-Term Blarcamesine Benefits For Early Alzheimer’s Patients